Company intelligence / Profile preview

LumiSTAR Biotechnology

Ownership: Private
Development stage: Preclinical

Overview

LumiSTAR is developing cell therapies and drugs using iPSC technology. Their pipeline includes products for inflammatory conditions, fibrosis, Parkinson's disease, kidney disease, and cancer, all currently in discovery or pre-clinical stages.

Therapeutic areas: NephrologyImmunologyOtherOncologyNeurology
Modalities: Cell therapySmall moleculesProtein-based indicators
Industry: Biotech

Partnerships

Molecular Devices (California-based)PanasonicJapanese company (unnamed)American company (unnamed)

Beyond the preview

Go deeper on LumiSTAR Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LumiSTAR Biotechnology.

Explore the full profile